Filter By
Search
-
OPERATING EXPENSES DOWN 20% AND CASH POSITION AT €1.7 M AT JUNE 30, 2025
1st half 2025 results EVRY, FRANCE, THURSDAY OCTOBER 29, 2025, 5:45 PM - IntegraGen (FR0010908723...
-
IntegraGen announces the appointment of Bérengère Génin as Chief Executive Officer
Évry, France, October 21, 2025 - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), a...
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
EVRY, FRANCE, THURSDAY JULY 13TH 2023, 7:30 AM - IntegraGen (FR0010908723 - ALINT - PEA eligible...
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45 pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), a...
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by...
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
Founded in 1961, the Centre Antoine Lacassagne is one of 18 cancer centers...
-
NEW LOOK. NEW PORTFOLIO. NEW OPPORTUNITIES.
FOLLOWING ITS ACQUISITION BY ONCODNA, INTEGRAGEN HAS UNDERGONE A COMPLETE OVERHAUL AND IS NOW...
-
POTENTIAL INVOLVEMENT OF URINARY TRACT INFECTIONS IN THE DEVELOPMENT OF BLADDER CANCER
Uropathogenic E.coli induces DNA damage in the bladder As provider of the whole genome sequencing, IntegraGen...
-
NEW PERSPECTIVES IN THE DIAGNOSIS AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset...
-
BRIEF TECHNIQUE: LOW-PASS WHOLE GENOME SEQUENCING - GETTING MORE FROM LESS
LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background Analysis of circulating tumor DNA...
